Literature DB >> 19293254

Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?

Richard F Ambinder1.   

Abstract

Splizimomab, an antibody that targets CD2, was studied in the treatment of T and natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19293254      PMCID： PMC5792055          DOI： 10.1158/1078-0432.CCR-08-2905

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.

Authors:  L J Swinnen; M R Costanzo-Nordin; S G Fisher; E J O'Sullivan; M R Johnson; A L Heroux; G J Dizikes; R Pifarre; R I Fisher
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

2.  Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

Authors:  Sylvain Choquet; Veronique Leblond; Raoul Herbrecht; Gérard Socié; Anne-Marie Stoppa; Peter Vandenberghe; Alain Fischer; Franck Morschhauser; Gilles Salles; Walter Feremans; Etienne Vilmer; Marie-Noelle Peraldi; Philippe Lang; Yvon Lebranchu; Eric Oksenhendler; Jeanne Luce Garnier; Thierry Lamy; Arnaud Jaccard; Augustin Ferrant; Fritz Offner; Olivier Hermine; Anne Moreau; Samira Fafi-Kremer; Patrice Morand; Lucienne Chatenoud; Nathalie Berriot-Varoqueaux; Loïc Bergougnoux; Noel Milpied
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

3.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Authors:  Joost W J van Esser; Hubert G M Niesters; Bronno van der Holt; Ellen Meijer; Albert D M E Osterhaus; Jan Willem Gratama; Leo F Verdonck; Bob Löwenberg; Jan J Cornelissen
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

5.  Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique.

Authors:  E Meijer; I C M Slaper-Cortenbach; S F T Thijsen; A W Dekker; L F Verdonck
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

6.  EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

Authors:  Deirdre O'Mahony; John C Morris; Maryalice Stetler-Stevenson; Helen Matthews; Margaret R Brown; Thomas Fleisher; Stefania Pittaluga; Mark Raffeld; Paul S Albert; Dirk Reitsma; Karen Kaucic; Luz Hammershaimb; Thomas A Waldmann; John E Janik
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

7.  Prompt versus preemptive intervention for EBV lymphoproliferative disease.

Authors:  Hans-Joachim Wagner; Yee Chung Cheng; M Helen Huls; Adrian P Gee; Ingrid Kuehnle; Robert A Krance; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2004-01-29       Impact factor: 22.113

8.  X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus.

Authors:  G C Faulkner; S R Burrows; R Khanna; D J Moss; A G Bird; D H Crawford
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103
  8 in total
  1 in total

1.  CD56- extranodal natural killer (NK)/T-cell lymphoma, nasal type presenting as skin ulcers in a white man.

Authors:  Charles Vainder; Jonhan Ho; Steven H Swerdlow; Oleg E Akilov
Journal:  JAAD Case Rep       Date:  2016-10-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.